Jazz Pharmaceuticals PLC
NASDAQ:JAZZ

Watchlist Manager
Jazz Pharmaceuticals PLC Logo
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Watchlist
Price: 169.7 USD 1.67% Market Closed
Market Cap: 10.3B USD

Jazz Pharmaceuticals PLC
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Jazz Pharmaceuticals PLC
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
EPS (Diluted)
-$5
CAGR 3-Years
-171%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Perrigo Company PLC
NYSE:PRGO
EPS (Diluted)
$0
CAGR 3-Years
22%
CAGR 5-Years
-56%
CAGR 10-Years
N/A
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
EPS (Diluted)
$0
CAGR 3-Years
83%
CAGR 5-Years
N/A
CAGR 10-Years
39%
G
GH Research PLC
NASDAQ:GHRS
EPS (Diluted)
$0
CAGR 3-Years
-53%
CAGR 5-Years
-137%
CAGR 10-Years
N/A
Cosmo Pharmaceuticals NV
SIX:COPN
EPS (Diluted)
€3
CAGR 3-Years
17%
CAGR 5-Years
N/A
CAGR 10-Years
-14%
Ovoca Bio PLC
LSE:OVB
EPS (Diluted)
€0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Jazz Pharmaceuticals PLC
Glance View

In the bustling world of global pharmaceuticals, Jazz Pharmaceuticals PLC has carved out a niche for itself through its focus on specialty pharmaceuticals addressing unmet medical needs. Founded in 2003, Jazz has grown significantly by acquiring and developing unique products that serve smaller patient populations but address significant health challenges. Its journey is one of careful strategy and thoughtful innovation. The company first gained attention with its sleep disorder portfolio, most notably Xyrem, a treatment for narcolepsy that quickly became a cornerstone of its revenue stream. Jazz's adeptness at navigating complex regulatory and market environments has played a crucial role in its success, allowing it to maintain a stronghold in niche therapeutic markets. Building on its initial successes, Jazz began to diversify its portfolio, expanding into oncology and neuroscience. The acquisition of companies like Celator Pharmaceuticals and GW Pharmaceuticals was a strategic move to broaden its research capabilities and tap into the lucrative, yet challenging, segments of cancer and cannabinoid therapies. Jazz’s pipeline is rich with promising candidates, reflecting its commitment to long-term growth through innovation. Central to its business model is the commercialization of these specialized, high-value drugs, which are marketed to healthcare providers and directly impact patient outcomes. By focusing on diseases with few effective treatments, Jazz positions itself as a leader in transforming lives, all while sustaining its financial health through carefully managed margins and a global reach in its distribution and research efforts.

JAZZ Intrinsic Value
298.07 USD
Undervaluation 43%
Intrinsic Value
Price

See Also

What is Jazz Pharmaceuticals PLC's EPS (Diluted)?
EPS (Diluted)
-6 USD

Based on the financial report for Sep 30, 2025, Jazz Pharmaceuticals PLC's EPS (Diluted) amounts to -6 USD.

What is Jazz Pharmaceuticals PLC's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 3Y
-171%

The average annual EPS (Diluted) growth rates for Jazz Pharmaceuticals PLC have been -171% over the past three years .

Back to Top